Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
Latest Information Update: 21 Feb 2024
At a glance
- Drugs TSHA 101 (Primary)
- Indications GM2 gangliosidoses
- Focus Adverse reactions; First in man
Most Recent Events
- 15 Feb 2024 According to a Taysha Gene Therapies media release, The Company transferred rights back to Queen's University (Queen's) for TSHA-101 in GM2 gangliosidosis, resulting in Queen's regaining exclusive IP to the program.
- 08 May 2023 Planned primary completion date changed from 12 Mar 2023 to 12 Mar 2027.
- 12 Sep 2022 Status changed from suspended to active, no longer recruiting.